Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosales, O.
Right arrow Articles by Giles, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rosales, O.
Right arrow Articles by Giles, T.

Chest, Vol 95, 43-47, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Carteolol, an antihypertensive beta-blocker with intrinsic sympathomimetic activity, reduces ECG evidence of left ventricular hypertrophy

OR Rosales, GE Sander, L Roffidal, MB Given and TD Giles
Medical Service, Veterans Administration Medical Center, New Orleans.

Effective treatment of chronic hypertension may be accompanied by a decrease, increase, or no change in the extent of LVH, depending on the pharmacologic properties of the antihypertensive agents employed. Unlike beta-adrenoceptor blockers without ISA, beta-adrenoceptor blockers with ISA have been reported to increase left ventricular mass despite favorable reductions in blood pressure. To assess further the potential effect of ISA on LVH, we retrospectively evaluated the effect of carteolol, a nonspecific beta-adrenoceptor antagonist with strong ISA, upon ECG evidence of LVH. In 12 patients with LVH, carteolol treatment for one year reduced mean arterial blood pressures from 120 +/- 2 mm Hg to 100 +/- 2 mm Hg and mean hypertrophy scores from 5.2 +/- 0.6 to 2.6 +/- 0.8. Therefore, ISA does not preclude the regression of ECG evidence of LVH during the treatment of hypertension.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.